Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.
Employees: 11-50
Total raised: $61M
Investors 2
| Date | Name | Website |
| 05.12.2023 | Forbion | forbion.co... |
| 10.11.2023 | Ysios Capi... | ysioscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.11.2023 | Series A | $61M | - |
Mentions in press and media 5
| Date | Title | Description |
| 14.11.2025 | - | LOUISVILLE, Ky., Nov. 14, 2025 /PRNewswire/ -- Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION® System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects wit... |
| 17.12.2024 | Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia | - KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the Phase 1 study in healthy volunteers - Initial d... |
| 29.05.2024 | Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases | Naarden, The Netherlands – May 29, 2024 – Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished S... |
| 26.12.2023 | These are the 10 biggest funding rounds of the Netherlands in 2023; 7 are from Amsterdam | Read this article in: In the last decade, the Netherlands has become one of Europe’s fastest-growing startup ecosystems. Fueled by a competitive talent pool, a complex yet interconnected economy, and a thriving tech sector, the country has ... |
| - | Kynexis | “Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.” |